The Business of Preclinical Research - Positive Market Dynamics

5,640 views
5,342 views

Published on

Part of the MaRS Best Practices series' pre-clinical development workshop

Speaker: Leigh Berryman, COO, Ricerca BioSciences
An introduction to the many changes the pharmaceutical industry has seen over the past decades as a business and as a science, and their implication to drug discovery and development today.

Published in: Business, Economy & Finance
1 Comment
1 Like
Statistics
Notes
  • Its very nice and good sharing and for your slides.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total views
5,640
On SlideShare
0
From Embeds
0
Number of Embeds
64
Actions
Shares
0
Downloads
463
Comments
1
Likes
1
Embeds 0
No embeds

No notes for slide

The Business of Preclinical Research - Positive Market Dynamics

  1. 1. The business of preclinical research - Positive market dynamics Leigh Berryman 1
  2. 2. Bio-pharmaceutical research The Business The Science • Virtual biotech companies • Patent protection of identified replacing global pharma in biological processes is key discovery • Large molecules of known • Goal is ‘added value’ as pharmacological activity opposed to marketed product • Focus on preclinical • Funding heavily reliant on development cf clinical marketing ‘hype’ • Focus on understanding at a • Companies have few platform molecular level technologies 2
  3. 3. Increased R&D spending Global R&D spending Pharma and 100 biotech spending $86 90 80 • Pipeline development $ US billions 70 $63 $57 60 $52 • Expanding biotechnology base $48 $45 50 $42 • Rising R&D costs per drug 40 30 • Financial markets focusing to 20 provide capital to virtual / 10 biotech developers 0 2000 2001 2002 2003 2004 2005 2008 Source: Kalorama information 3
  4. 4. Total R&D outsourcing Outsourced global CRO R&D spending Pharma & biotech spending outsourced 24 40 Percentage of R&D outsourced $21 to CROs 20 35 $ US billions • Faster, cost-efficient 16 30 $13 alternative $11 25 12 $10 • Access to critical expertise $8 24% $7 20 8 21% $6 19% 19% • Biotech industry growth 15 4 17% 16% 14% • Pharma reducing 0 0 CapEx spending 2000 2001 2002 2003 2004 2005 2008 Source: Kalorama information 4
  5. 5. Preclinical outsourcing segment $4 Billion - 16% CAGR (2005-2008) Source: Kalorama information 1 FDA 5,000 - 10,000 Preclinical Phase III Approved Phase II Phase I New Drug Drug Candidates Global Global 60% 7% 13% 20% R&D projects R&D projects Fastest growing outsourcing market segment • Critical stage of drug development process • Project termination once commenced is unlikely • High barriers to entry 5
  6. 6. Barriers to entry 6 Facilities Client Credibility Personnel Regulatory Capital intensive Established Access Highly and highly track records to skilled & regulated specialized of quality and experienced environment facilities on-time delivery scientific personnel Disciplined Competitive Environment 6
  7. 7. A speculative thought….. The paradigm • Funding is through investment groups looking for a return on investment • Biotech companies provide early research and intellectual property • The CROs provide developmental services (preclinical/clinical/manufacturing) • Large investment funds now include both biotech and CROs Are we seeing the emergence of the investment group as the new global pharma of the future ? 7
  8. 8. Today’s Agenda The process of drug development • Early Stage drug discovery and lead optimization (going fishing ?) • Production of the active product and scale-up • Does it work ? Biological models • Is it safe ? Toxicity • Can we bring it to the market ? Regulatory 8

×